Aspire Biopharma Holdings annual total liabilities
2021
2022
2023
2024
2025
Aspire Biopharma Holdings Total Liabilities Growth & History (ASBP)
Aspire Biopharma Holdings's total liabilities was $7.7M for fiscal 2025.
View full Aspire Biopharma Holdings company overviewAspire Biopharma Holdings annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.7M | $6.0M | +355.46% |
| 2024 | 2024-12-31 | $1.7M | $1.3M | +318.54% |
| 2023 | 2023-12-31 | $403,328 | −$10.7M | −96.37% |
| 2022 | 2022-12-31 | $11.1M | $10.8M | +3684.81% |
| 2021 | 2021-12-31 | $293,696 | — | — |
Aspire Biopharma Holdings quarterly total liabilities
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | −$8.8M | −83.19% |
| Q1 2026 | 2026-03-31 | $3.2M | −$5.7M | −63.57% |
| Q4 2025 | 2025-12-31 | $7.7M | $6.0M | +355.46% |
| Q3 2025 | 2025-09-30 | $13.9M | $7.3M | +111.02% |
| Q2 2025 | 2025-06-30 | $10.6M | $4.4M | +69.96% |
| Q1 2025 | 2025-03-31 | $8.9M | $6.3M | +238.66% |
| Q4 2024 | 2024-12-31 | $1.7M | $1.3M | +318.54% |
| Q3 2024 | 2024-09-30 | $6.6M | $6.3M | +1977.95% |
| Q2 2024 | 2024-06-30 | $6.2M | $6.0M | +2094.53% |
| Q1 2024 | 2024-03-31 | $2.6M | −$8.5M | −76.42% |
| Q4 2023 | 2023-12-31 | $403,328 | −$10.7M | −96.37% |
| Q3 2023 | 2023-09-30 | $316,316 | −$10.7M | −97.12% |
| Q2 2023 | 2023-06-30 | $284,356 | −$10.7M | −97.41% |
| Q1 2023 | 2023-03-31 | $11.2M | $304,665 | +2.80% |
| Q4 2022 | 2022-12-31 | $11.1M | $10.8M | +3684.81% |
| Q3 2022 | 2022-09-30 | $11.0M | — | — |
| Q2 2022 | 2022-06-30 | $11.0M | — | — |
| Q1 2022 | 2022-03-31 | $10.9M | — | — |
| Q4 2021 | 2021-12-31 | $293,696 | — | — |
Aspire Biopharma Holdings total liabilities trends
Between the periods ended 2021-12-31 and 2025-12-31, Aspire Biopharma Holdings's total liabilities increased from $293,696 to $7.7M, a change of $7.4M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aspire Biopharma Holdings source filings ↗